目的 探究过敏性鼻炎(AR)患者血清脂氧素A4(LXA4)、半乳糖凝集素-3(Gal-3)水平与其病情进展的关系。方法 纳入2022-07至2023-10解放军总医院京南医疗区门诊就诊的113例AR患者为AR组,根据世界卫生组织的分级标准分为轻度组48例,中重度组65例。同时选取110例健康志愿者为对照组。血清LXA4、Gal-3水平采用酶联免疫吸附试剂盒测定,收集AR患者一般资料。变量间的相关分析采用Spearman相关检验。使用受试者工作特征(ROC)曲线来评估血清LXA4、Gal-3水平区分AR不同严重程度的能力。采用Logistic回归分析AR疾病严重程度的影响因素。结果 与对照组相比,AR组血清LXA4、Gal-3水平明显升高(P<0.05)。中重度组视觉模拟量表评分(VAS)、鼻部症状评分(TNSS)、血清LXA4、Gal-3水平显著高于轻度组(P<0.05)。Spearman相关分析显示,AR患者血清LXA4、Gal-3水平与VAS、TNSS评分均呈正相关(P<0.05)。血清LXA4、Gal-3及两者联合诊断中重度AR发生的AUC分别为0.829、0.812、0.912,显著高于单独检测(Z联合-LXA4=3.076、Z联合-Gal-3=2.940,P<0.05)。血清LXA4、Gal-3水平是影响中重度AR发生的独立危险因素(P<0.05)。结论 血清LXA4、Gal-3在AR患者中水平升高,且与其病情进展关系密切。
Abstract
Objective To investigate the relationship between serum levels of lipoxin A4 (LXA4) and galactin-3 (Gal-3) and disease progression in patients with allergic rhinitis (AR). Methods A total of 113 AR patients admitted to the outpatient department of Jingnan Medical District of PLA General Hospital from July 2022 to October 2023 were included as AR group, and were divided into mild group (48 cases) and moderate and severe group (65 cases) according to the grading standard of the World Health Organization. Meanwhile,110 healthy volunteers were selected as control group. Serum levels of LXA4 and Gal-3 were measured by enzyme-linked immunosorbent kit. General data of AR patients was collected. The correlation analysis between variables was conducted using Spearman correlation test. Receiver operating characteristic (ROC) curve was applied to evaluate the ability of serum LXA4 and Gal-3 levels to distinguish different severity of AR. Logistic regression was used to analyze the influencing factors of AR disease severity. Results Compared with the control group, serum levels of LXA4 and Gal-3 in AR group obviously increased (P<0.05). VAS, TNSS scores, serum LXA4 and Gal-3 levels in the moderate and severe group were obviously higher than those in mild group (P<0.05). Spearman correlation analysis showed that serum levels of LXA4 and Gal-3 were positively correlated with VAS and TNSS scores in AR patients (P<0.05). The AUC of serum LXA4, Gal-3, and their combination in the diagnosis of moderate and severe AR were 0.829, 0.812, and 0.912, respectively, which were obviously higher than that of single detection (Z combination-LXA4=3.076, Z combination-Gal-3=2.940, P<0.05). Serum LXA4 and Gal-3 levels were independent risk factors for the occurrence of moderate and severe AR (P<0.05). Conclusions The levels of serum LXA4 and Gal-3 are elevated in AR patients and are closely related to disease progression.
关键词
过敏性鼻炎 /
病情进展 /
脂氧素A4 /
半乳糖凝集素-3
Key words
allergic rhinitis /
disease progression /
lipoxin A4 /
galectin-3
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Siddiqui Z A, Walker A, Pirwani M M, et al. Allergic rhinitis: diagnosis and management[J]. Br J Hosp Med (Lond), 2022, 83(2):1-9.
[2] Sheha D, El-Korashi L, AbdAllah A M, et al. Lipid profile and IL-17A in allergic rhinitis: correlation with disease severity and quality of life[J]. J Asthma Allergy, 2021, 14:109-117.
[3] Awan N U, Sohail S K, Naumeri F, et al. Association of serum vitamin D and immunoglobulin E levels with severity of allergic rhinitis[J]. Cureus, 2021, 13(1):e12911.
[4] Peng X, Zhu X, Luan J, et al. Lipoxin A4 alleviates inflammation in Aspergillus fumigatus-stimulated human corneal epithelial cells by Nrf2/HO-1 signaling pathway[J]. Mol Vis, 2022, 28:441-450.
[5] 吴莉芳,张 麟,张 杰,等. 变应性鼻炎患者血清PTX3,LXA4表达水平及临床价值研究[J]. 现代检验医学杂志,2023,38(2):140-145.
[6] Soares L C, Al-Dalahmah O, Hillis J, et al. Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases[J]. Cells, 2021, 10(11):3047.
[7] 董 健,曾 鹏,车立纯,等. 血清高迁移率族蛋白B1、白细胞介素-1β及半乳糖凝集素-3对过敏性哮喘患儿病情发展的诊断价值[J]. 中国临床医生杂志,2022,50(9):1108-1110.[8] Dykewicz M S, Wallace D V, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update[J]. Ann Allergy Asthma Immunol, 2017, 119(6):489-511.
[9] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志,2022,57(2):106-129.
[10] Xing X, Wang H. Correlation of serum HMGB1 and HMGB2 levels with clinical symptoms in allergic rhinitis children[J]. Medicine (Baltimore), 2023, 102(37):e34921.
[11] Wang R, Xue S, Liu Y, et al. The correlation of long non-coding RNA NEAT1 and its targets microRNA (miR)-21, miR-124, and miR-125a with disease risk, severity, and inflammation of allergic rhinitis[J]. Medicine (Baltimore), 2021, 100(4):e22946.
[12] Zhao J, Geng W, Wan K, et al. Lipoxin A4 promotes autophagy and inhibits overactivation of macrophage inflammasome activity induced by Pg LPS[J]. J Int Med Res, 2021, 49(2):300060520981259.
[13] Zhang L, Tai Q, Xu G, et al. Lipoxin A4 attenuates the lung ischaemia reperfusion injury in rats after lung transplantation[J]. Ann Med, 2021, 53(1):1142-1151.
[14] Li Q Q, Ding D H, Wang X Y, et al. Lipoxin A4 regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the Notch signaling pathway[J]. Exp Neurol, 2021, 339:113645.
[15] Hu F, Qu Z, Chen K, et al. Lipoxin A4 ameliorates imiquimod-induced psoriasis-like dermatitis via promoting the regression of inflammation[J]. Clin Cosmet Investig Dermatol, 2023, 16:2103-2111.
[16] Ramar M, Yano N, Fedulov A V. Intra-airway treatment with synthetic lipoxin A4 and resolvin E2 mitigates neonatal asthma triggered by maternal exposure to environmental particles[J]. Int J Mol Sci, 2023, 24(7):6145.
[17] Lo T H, Chen H L, Yao C I, et al. Galectin-3 promotes noncanonical inflammasome activation through intracellular binding to lipopolysaccharide glycans[J]. Proc Natl Acad Sci U S A, 2021, 118(30):e2026246118.
[18] Li H, Xiao L, He H, et al. Quercetin attenuates atherosclerotic inflammation by inhibiting galectin-3-NLRP3 signaling pathway[J]. Mol Nutr Food Res, 2021, 65(15):e2000746.
[19] Karabacak P. Serum galectin-3 levels predict poor prognosis in sepsis and septic shock patients[J]. Rev Assoc Med Bras (1992), 2023, 69(8):e20220940.
[20] Mammen M J, Ali J, Aurora A, et al. IL-17 is a key regulator of mucin-galectin-3 interactions in asthma[J]. Int J Cell Biol, 2021, 2021:9997625.
PDF(1075 KB)
